Invitation to the Special and Extraordinary Shareholders' Meetings of 26 July 2016 - Nomination of Mary Kerr for Galapagos' Board of Directors
(Thomson Reuters ONE) -
Mechelen, Belgium; 23 June 2016 - Galapagos NV (Euronext & NASDAQ: GLPG) has the
honor to invite its Shareholders, Warrant Holders, Directors and Statutory
Auditor to its Special and Extraordinary Shareholders' Meetings that will be
held on Tuesday 26 July 2016 at 2 pm CET at the offices of notary public
Matthieu Derynck (Van Halteren, associated notaries public, Rue de Ligne
13, 1000 Brussels).
Galapagos announces that Dr. Mary Kerr has been nominated to join the Board of
Directors of Galapagos, subject to shareholder approval during the Special
Shareholders' Meeting on 26 July 2016. Dr. Kerr, a UK national, is Chief
Executive Officer and Director at NeRRe Therapeutics. Prior to her appointment
at NeRRe, Mary held a range of senior leadership roles at GSK over more than 20
years, most recently as Senior Vice President and Global Franchise leader for
the Immuno-inflammation and Infectious Diseases franchise. Mary was a founding
member and on the Corporate Executive team of ViiV Healthcare where she led a
turnaround in the performance of the HIV business in Europe. She has spent the
majority of her career on the R&D commercial interface in global strategy and
regional operational roles, predominantly in the specialty and orphan space.
Mary gained a Ph.D. in Pharmacology at the University of Bradford, did post-
doctoral research at the Michigan Cancer Foundation in Detroit and has an MBA
from the University of Kingston. She is also an Operating Partner with Advent
Life Sciences, one of NeRRe Therapeutics' investors, since October 2015.
In order to be admitted to the Shareholders' Meetings, the holders of securities
issued by the Company must comply with article 536 of the Belgian Companies Code
and article 29 of the Company's articles of association, and fulfill the
formalities described in the convening notices.
The convening notice and other documents pertaining to the Shareholders'
Meetings can be consulted at www.glpg.com/shareholders-meetings.
About Galapagos
Galapagos(Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company
specialized in the discovery and development of small molecule medicines with
novel modes of action. Our pipeline comprises Phase 2, Phase 1, pre-clinical and
discovery studies in cystic fibrosis, inflammation, fibrosis, osteoarthritis and
other indications. We have discovered and developed filgotinib: in collaboration
with Gilead we aim to bring this JAK1-selective inhibitor for inflammatory
indications to patients all over the world. Galapagos is focused on the
development and commercialization of novel medicines that will improve people's
lives. The Galapagos group, including fee-for-service subsidiary Fidelta, has
approximately 440 employees, operating from its Mechelen, Belgium headquarters
and facilities in The Netherlands, France, and Croatia. More information at
www.glpg.com.
Contacts
Investors: Media:
Elizabeth Goodwin Evelyn Fox
VP IR & Corporate Communications Director Communications
+1 781 460 1784 +31 6 53 591 999
communications(at)glpg.com
Paul van der Horst
Director IR & Business Development
+31 6 53 725 199
ir(at)glpg.com
Forward-looking statements
This release may contain forward-looking statements. Such forward-looking
statements are not guarantees of future results. These forward-looking
statements speak only as of the date of publication of this document. Galapagos
expressly disclaims any obligation to update any forward-looking statements in
this document, unless specifically required by law or regulation.
Invitation to EGM and nomination Mary Kerr:
http://hugin.info/133350/R/2022669/751483.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via GlobeNewswire
[HUG#2022669]
Unternehmensinformation / Kurzprofil:
Datum: 23.06.2016 - 07:30 Uhr
Sprache: Deutsch
News-ID 479528
Anzahl Zeichen: 4715
contact information:
Town:
Mechelen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 340 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Invitation to the Special and Extraordinary Shareholders' Meetings of 26 July 2016 - Nomination of Mary Kerr for Galapagos' Board of Directors"
steht unter der journalistisch-redaktionellen Verantwortung von
Galapagos NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
